SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000905148-20-000504
Filing Date
2020-04-16
Accepted
2020-04-16 12:47:05
Documents
2

Document Format Files

Seq Description Document Type Size
1 efc20-346_sc13da.htm SC 13D/A 194249
2 efc20-346_ex993.htm EX-99.3 11039
  Complete submission text file 0000905148-20-000504.txt   207006
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
Menlo Therapeutics Inc. (Subject) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90268 | Film No.: 20795717
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 415-522-0100
venBio Global Strategic Fund II L.P. (Filed by) CIK: 0001634632 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D/A